• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article (55080193)   Find a Category (126)   Find a Journal (6146)   Find a Scholar (3941)   Find an Academic Assistant (17)
Find an Article PDF (4595230)   Today's Articles (9)   Subscriber (49331)
Citation(s) in RCA

Indexed Articles
Ranked By
Results Analysis
  •   
  •   
  •   
  •   
Results Analysis
For: Pantazi D, Ntemou N, Brentas A, Alivertis D, Skobridis K, Tselepis AD. Molecular Requirements for the Expression of Antiplatelet Effects by Synthetic Structural Optimized Analogues of the Anticancer Drugs Imatinib and Nilotinib. Drug Des Devel Ther 2019;13:4225-4238. [PMID: 31849454 PMCID: PMC6913343 DOI: 10.2147/dddt.s211907] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/17/2019] [Accepted: 08/12/2019] [Indexed: 01/05/2023]
Number Cited by Other Article(s)
1
Pantazi D, Tselepis AD. Cardiovascular toxic effects of antitumor agents: Pathogenetic mechanisms. Thromb Res 2022;213 Suppl 1:S95-S102. [DOI: 10.1016/j.thromres.2021.12.017] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2021] [Revised: 12/06/2021] [Accepted: 12/16/2021] [Indexed: 02/08/2023]
2
Voulgari P, Alivertis D, Skobridis K. Improvements in the Synthesis of the Third‐Generation EGFR Inhibitor Osimertinib. Helv Chim Acta 2021. [DOI: 10.1002/hlca.202100066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA